Re: GNT
You ask a lot of questions for which I unfortunately do not have answers. I know very little about this company other than what I heard on a recent webcast. And I didn’t absorb as much from the webcast as I would have liked because the CEO, Dr Laura Ferro, has a thick Italian accent and the webcast sound quality wasn’t that great.
With the huge run-up in the prices of many small biotechs during the current bull run, there are relatively few pockets of deep value remaining. Foreign companies (including Canadian) and those with offbeat business models (e.g. GTCB) are exceptions. GNT has both of these attributes, so I thought it might be worth investigating further, but I haven’t done it yet.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”